Biovail Concerned Shareholders Welcome Glass Lewis Evaluation



    
    Independent Report Sharply Criticizes Current Management

    Recommends 'Do Not Vote' For Any of the Company's Nominees
    

    TORONTO, June 18 /CNW/ -- The Concerned Shareholders of Biovail
Corporation (NYSE:   BVF)(TSX: BVF) said today that they welcomed a report by
Glass Lewis & Co., which sharply criticized the incumbent board and
recommended 'Do Not Vote' for any of the company's nominees.
    Glass Lewis recommended a vote FOR two of the Concerned Shareholders
nominees, Joseph J. Krivulka and Laurence W. Zeifman. It recommended
withholding votes from the other eight nominees on the Concerned Shareholders'
slate.
    The Glass Lewis report took issue with several actions by the current
board, particularly its executive appointments and compensation packages.
    "While the board should be seeking to put its troubled history in the
past, it has instead appointed its former CEO as chairman and a former member
of an audit committee which oversaw significant restatements as its new CEO,"
the report says. "We believe that shareholders could benefit from the addition
of new independent voices on the board with appropriate subject matter and
industry expertise."
    The Glass Lewis report called the appointment of Biovail's CEO, William
Wells, "a curious choice at best," as well as "inappropriate from a corporate
governance perspective." It concludes: "At the very least such an appointment
could only further serve to damage the Company's already bruised public
image."
    Glass Lewis also expressed disapproval of executive compensation
arrangements made by the incumbent board. It notes that Mr. Wells chaired the
compensation and nominating committees, and that the retiring CEO, Douglas
Squires, was awarded a package of $3.5 million, including a retroactive raise,
even though the company's share price was falling.
    "An outside observer would conclude that these potentially excessive
compensation awards for Messrs. Squires and Wells, especially at a time of
poor financial performance, may be related to the appointment of Mr. Wells,"
the report says. "Even if Mr. Wells' past position in overseeing the committee
which determines executive pay and identified the new CEO did not affect his
appointment as CEO or the generous contracts for him and his predecessor, the
mere appearance of corruption could be damaging."
    Bruce D. Brydon, CEO of Biovail during some of its most successful years,
who will return as CEO if the Concerned Shareholders' slate is elected, said
he wants to get the company back on the right track. Mr. Brydon said: "We
believe that Biovail needs a complete change in its board, senior management
and direction to avoid even further declines in shareholder value."
    
    Mr. Brydon noted that:
    
    -- In the last year the price of Biovail stock has declined nearly 50%,
far worse than the drug industry stock price index.
    -- In the last four years, under current management, Biovail has obtained
regulatory approval for only one new drug, in sharp contrast to the 17 new
drugs that were approved during Mr. Brydon's tenure as CEO from 1995 to 2001.
    -- A leading financial analyst who covers Biovail and other drug
companies has stated that the new strategic direction announced recently by
Biovail's current management, to focus intensive research and development on
new chemical entities to treat central nervous system conditions such as
Alzheimer's Disease, "is just baffling to us."
    All shareholders are urged to vote the YELLOW proxy in favour of the
Concerned Shareholders slate of nominees. Copies of the proxy circular
prepared by the Concerned Shareholders can be obtained via SEDAR
(www.sedar.com) and www.betterbiovail.com or by contacting in Canada,
Kingsdale Shareholder Services Inc. toll-free at 1-800-775-1986 or collect at
1-416-867-2272, or in the United States, Innisfree M&A Incorporated toll-free
at 1-877-717-3929.
    Certain statements contained in this release constitute forward-looking
statements. The words "may", "would", "could", "will", "intend", "plan",
"anticipate", "believe", "estimate", "expect" and similar expressions as they
relate to the Concerned Shareholders, the Concerned Shareholders' nominees,
the Company or its current or future management, are intended to identify
forward-looking statements. Such statements reflect the Concerned
Shareholders' or the Concerned Shareholders' nominees' current views with
respect to future events and are subject to certain risks, uncertainties and
assumptions. The Concerned Shareholders' nominees assume no responsibility for
any such statements. Many factors could cause the company's actual results,
performance or achievements that may be expressed or implied by such forward-
looking statements to vary from those described herein should one or more of
these risks or uncertainties materialize. Such factors include, but are not
limited to, economic, business, technological, competitive and regulatory
factors.
    Bruce Brydon




For further information:

For further information: Canadian Media, Duncan Fulton of 
Fleishman-Hillard, +1-416-645-3655, duncan.fulton@fleishman.ca; or US Media, 
Mike Sitrick of Sitrick And Company, +1-310-788-2850, 
mike_sitrick@sitrick.com, both for Bruce Brydon Web Site:
http://www.betterbiovail.com

Organization Profile

CONCERNED SHAREHOLDERS OF BIOVAIL

More on this organization


Custom Packages

Browse our custom packages or build your own to meet your unique communications needs.

Start today.

CNW Membership

Fill out a CNW membership form or contact us at 1 (877) 269-7890

Learn about CNW services

Request more information about CNW products and services or call us at 1 (877) 269-7890